Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03071692 · ClinicalTrials.gov registry record · Phase 3
Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)
A Phase 3 study, sponsored by Kowa Research Institute.
- Terminated
- Registry status
- Phase 3
- Development phase
- 10,544
- Enrollment target
NCT03071692: Clinical Trial Phase 3 study, sponsored by Kowa Research Institute.
NCT03071692 is a Phase 3 study that was terminated before completion, run by Kowa Research Institute. The registered enrollment target is 10,544 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1268% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03071692, a Phase 3 study, was terminated before completion, sponsored by Kowa Research Institute.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 10,544 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine whether pemafibrate administered twice daily will delay the time to first occurrence of any component of the clinical composite endpoint of: * nonfatal Myocardial Infarction (MI) * nonfatal ischemic stroke * coronary revascularization; or * Cardio Vascular (CV) death.
Primary Outcome
Number of participants experiencing their first occurrence of any component of the 4-component composite primary endpoint, which includes nonfatal myocardial infarction (MI), nonfatal ischemic stroke, coronary revascularization, or cardiovascular (CV) death. Each participant is counted only once, regardless of any subsequent events.
Interventions
- DRUG Placebo
- DRUG K-877
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,544 participants |
| Start Date | 2017-03-23 |
| Est. Completion | 2022-07-27 |
| Phase | Phase 3 |
Why NCT03071692 stopped before completion
NCT03071692 is an interventional study that assigns participants to a tested intervention. Its 10,544 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1268% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03071692 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03071692 about?
NCT03071692 is a clinical study titled "Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)". The primary objective of the study is to determine whether pemafibrate administered twice daily will delay the time to first occurrence of any component of the clinical composite endpoint of: * nonfatal Myocardial Infarction (MI) * nonfatal ischemic stroke * coronary revascularization; or * Cardio ...
What is the current status of trial NCT03071692?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 10,544 participants. The study started on 2017-03-23. Estimated completion is 2022-07-27.
What interventions are being tested in trial NCT03071692?
The interventions under investigation include: Placebo (DRUG), K-877 (DRUG).
Who is sponsoring clinical trial NCT03071692?
This trial is sponsored by Kowa Research Institute, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03071692's enrollment target sits among peer trials
10,544 25th of 2000 higher than 1,976 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05759299 · 10,500 participants
International obServational sTudy on AiRway manaGement in operAting Room and Non-operaTing Room anaEsthesia
- NCT06891222 · 10,500 participants
A Study of Electrocardiogram and Focused Cardiac Ultrasound for Enhanced Cardiac Disease Screening
- NCT06081517 · 10,600 participants
Evaluating Disparities in Precision Oncology
- NCT07157774 · 10,450 participants · Phase 3
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI